Hexun Biosciences announced that it has successfully obtained INCI (International Nomenclature of Cosmetic Ingredients) certification for its proprietary mesenchymal stem cell-secreted exosomes (MSC-exo) to be included in the list of ingredients for cosmetic products, signalling its expansion into the global cosmetics and skin care markets.

Hexun Biosciences said that the company's exosomes are secreted by mesenchymal stem cell bank in accordance with international ICH regulations, with the ability to promote collagen proliferation, anti-aging and other capabilities, and has been verified to have a high degree of safety without skin or eye irritation, and can be used not only as ingredients for cosmetics and nutraceuticals, but also for the development of new drugs that have the function of immune regulation, regeneration and repair, or drug carriers, and have a wide range of applications.

The company also stated that in the process of developing drugs using mesenchymal stem cells, it is also developing stem cell-derived exosomes. With its experience in cellular drug discovery and 33 patents, the company has mastered the mass production, purification and identification of high-quality clinical-grade cell banks and exosomes, and has been able to produce large quantities of high-quality, high-purity exosomes with high efficiency for specific use. Exosomes are not only a key to Hexun Biosciences' success in gaining INCI accreditation, but also the main reason why the company has recently won a new CDMO contract for exosomes.

Hexun Biosciences is looking to collaborate with more diverse industries in the development of related cosmetic and skin care products, as well as in the discovery and development of new drugs, which will provide sustainable momentum for the growth of the company's CDMO business.

Hexun revealed its December 2023 revenue of NT$39.16 million, benefiting from CDMO business new and old customers, which contributed to the 96% monthly increase in December revenue, also increased by 324% compared to the same period last year; the full-year 2023 consolidated revenue reached NT$130 million, with an annual growth rate of 164%, and both December 2023 and full-year revenue hit record highs.